- Home
- RMTI vs ACET Comparison
RMTI vs ACET Comparison
Compare RMTI & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMTI | ACET |
|---|---|---|
| Founded | 1994 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 93.5M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | RMTI | ACET |
|---|---|---|
| Price | $0.92 | $0.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | ★ $8.50 |
| AVG Volume (30 Days) | 303.9K | ★ 1.9M |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $75,577,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $0.45 |
| 52 Week High | $2.41 | $1.12 |
Technical Indicators
Market Signals| Indicator | RMTI | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 34.97 |
| Support Level | $0.91 | $0.53 |
| Resistance Level | $1.02 | $0.57 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 37.47 | 20.77 |
Price Performance
Historical ComparisonAbout RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.